Advanced

Hypogonadism in young men treated for cancer.

Giwercman, Aleksander LU and Giwercman, Yvonne LU (2015) In Hormones: International Journal of Endocrinology and Metabolism 14(4). p.392-398
Abstract
An ever-increasing proportion of young males treated for cancer are cured. Therefore, one of the major challenges of modern Clinical Oncology is to ensure good quality of life. Cancer disease per se as well as cancer treatment may have a negative impact on androgen production, thereby leading to subclinical or clinically overt hypogonadism. Since the symptoms of androgen deficiency are rather unspecific, it is important that reproductive hormone levels be checked in young men who have been treated for cancer. As androgen deficiency in men is associated with increased long-term risk of osteoporosis as well as cardiovascular and metabolic disease, those cancer survivors who present with signs of insufficient androgen production should be... (More)
An ever-increasing proportion of young males treated for cancer are cured. Therefore, one of the major challenges of modern Clinical Oncology is to ensure good quality of life. Cancer disease per se as well as cancer treatment may have a negative impact on androgen production, thereby leading to subclinical or clinically overt hypogonadism. Since the symptoms of androgen deficiency are rather unspecific, it is important that reproductive hormone levels be checked in young men who have been treated for cancer. As androgen deficiency in men is associated with increased long-term risk of osteoporosis as well as cardiovascular and metabolic disease, those cancer survivors who present with signs of insufficient androgen production should be followed and preventive as well as therapeutic measures, including androgen replacement therapy, should be applied according to the current guidelines. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Hormones: International Journal of Endocrinology and Metabolism
volume
14
issue
4
pages
392 - 398
publisher
Hellenic Endocrine Society
external identifiers
  • pmid:26859600
  • scopus:84957625702
ISSN
1109-3099
DOI
10.14310/horm.2002.1650
language
English
LU publication?
yes
id
c6907213-30b3-4479-b116-a0431c32de57 (old id 8826072)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26859600?dopt=Abstract
date added to LUP
2016-03-03 14:19:14
date last changed
2017-01-01 07:52:50
@article{c6907213-30b3-4479-b116-a0431c32de57,
  abstract     = {An ever-increasing proportion of young males treated for cancer are cured. Therefore, one of the major challenges of modern Clinical Oncology is to ensure good quality of life. Cancer disease per se as well as cancer treatment may have a negative impact on androgen production, thereby leading to subclinical or clinically overt hypogonadism. Since the symptoms of androgen deficiency are rather unspecific, it is important that reproductive hormone levels be checked in young men who have been treated for cancer. As androgen deficiency in men is associated with increased long-term risk of osteoporosis as well as cardiovascular and metabolic disease, those cancer survivors who present with signs of insufficient androgen production should be followed and preventive as well as therapeutic measures, including androgen replacement therapy, should be applied according to the current guidelines.},
  author       = {Giwercman, Aleksander and Giwercman, Yvonne},
  issn         = {1109-3099},
  language     = {eng},
  number       = {4},
  pages        = {392--398},
  publisher    = {Hellenic Endocrine Society},
  series       = {Hormones: International Journal of Endocrinology and Metabolism},
  title        = {Hypogonadism in young men treated for cancer.},
  url          = {http://dx.doi.org/10.14310/horm.2002.1650},
  volume       = {14},
  year         = {2015},
}